Skip to content
Politically.com Search all
Menu

2026 · 2nd Quarter (Apr 1 - June 30)

AMGEN INC

Filed by TIBER CREEK GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 19, 2026
Income
$60,000.00
Expenses
Not reported
Client
AMGEN INC
Filing UUID
2633ba3d-f28b-47bd-84f2-6f9295827ae6
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability.

HCR · Health Issues

Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.

Literal federal measure citations: H.R. 5526, S. 1954

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.